Neoadjuvant weekly paclitaxel (wP) and carboplatin (Cb) with trastuzumab (T) and pertuzumab (P) in HER2-positive breast cancer (H plus BC): A Brown University oncology group (BrUOG) study

被引：1
|
作者：
Lopresti, Mary Lorraine [1 ]
Bian, Jessica J. [1 ]
Sakr, Bachir J. [2 ]
Strenger, Rochelle S. [1 ]
Legare, Robert D. [2 ]
Fenton, Mary Anne [1 ]
Witherby, Sabrina M. [1 ]
Dizon, Don S. [1 ]
Pandya, Sonali V. [2 ]
Stuckey, Ashley R. [2 ]
Edmondson, David A. [2 ]
Gass, Jennifer S. [2 ]
Emmick, Christine M. [1 ]
Graves, Theresa A. [1 ]
Cutitar, Marlene [1 ]
Olszewski, Adam J. [1 ]
Sikov, William M. [2 ]
机构：
[1] Lifespan Canc Inst, Providence, RI USA
[2] Women & Infants Hosp Rhode Isl, Providence, RI 02908 USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS19-P2-16-19
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-16-19
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Neoadjuvant weekly paclitaxel and carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer: a Brown University Oncology Research Group (BrUOG) study
    Lopresti, M. L.
    Bian, J. J.
    Sakr, B. J.
    Strenger, R. S.
    Legare, R. D.
    Fenton, M.
    Witherby, S. M.
    Dizon, D. S.
    Pandya, S. V.
    Stuckey, A. R.
    Edmondson, D. A.
    Gass, J. S.
    Emmick, C. M.
    Graves, T. A.
    Cutitar, M.
    Olszewski, A. J.
    Sikov, W. M.
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 189 (01) : 93 - 101
  • [2] Neoadjuvant weekly paclitaxel and carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer: a Brown University Oncology Research Group (BrUOG) study
    M. L. Lopresti
    J. J. Bian
    B. J. Sakr
    R. S. Strenger
    R. D. Legare
    M. Fenton
    S. M. Witherby
    D. S. Dizon
    S. V. Pandya
    A. R. Stuckey
    D. A. Edmondson
    J. S. Gass
    C. M. Emmick
    T. A. Graves
    M. Cutitar
    A. J. Olszewski
    W. M. Sikov
    Breast Cancer Research and Treatment, 2021, 189 : 93 - 101
  • [3] Neoadjuvant q4week carboplatin and weekly paclitaxel ± trastuzumab in resectable and locally advanced breast cancer:: A Brown University Oncology Group (BrUOG) study.
    Ries, LM
    Fenton, MA
    Dizon, DS
    Gass, JS
    Graves, TA
    Strenger, RS
    Sikov, WM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 67S - 67S
  • [4] Effect of Weekly Carboplatin and Paclitaxel with Trastuzumab and Pertuzumab (wPCbTP) on Nodal Disease and Surgical Options in HER2-positive Breast Cancer
    Ciambella, Chelsey
    Dizon, Don
    Taneja, Charu
    Graves, Theresa
    Lopresti, Mary
    Sikov, William
    ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (SUPPL 2) : S421 - S422
  • [5] Paclitaxel, Carboplatin, and Trastuzumab in a Neoadjuvant Regimen for HER2-Positive Breast Cancer: The TRAIN Study.
    Sonke, G. S.
    Mandjes, I. A.
    Holtkamp, M.
    Schot, M.
    Oosterkamp, H. M.
    Wesseling, J.
    Vrancken, Peeters M-J T.
    Rodenhuis, S.
    Linn, S. C.
    CANCER RESEARCH, 2011, 71
  • [6] Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
    Bianchini, Giampaolo
    Kiermaier, Astrid
    Bianchi, Giulia Valeria
    Im, Young-Hyuck
    Pienkowski, Tadeusz
    Liu, Mei-Ching
    Tseng, Ling-Ming
    Dowsett, Mitch
    Zabaglo, Lila
    Kirk, Sarah
    Szado, Tania
    Eng-Wong, Jennifer
    Amler, Lukas C.
    Valagussa, Pinuccia
    Gianni, Luca
    BREAST CANCER RESEARCH, 2017, 19
  • [7] Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
    Giampaolo Bianchini
    Astrid Kiermaier
    Giulia Valeria Bianchi
    Young-Hyuck Im
    Tadeusz Pienkowski
    Mei-Ching Liu
    Ling-Ming Tseng
    Mitch Dowsett
    Lila Zabaglo
    Sarah Kirk
    Tania Szado
    Jennifer Eng-Wong
    Lukas C. Amler
    Pinuccia Valagussa
    Luca Gianni
    Breast Cancer Research, 19
  • [8] Weekly paclitaxel, pertuzumab and trastuzumab (TPH) neoadjuvant therapy for HER2 positive inflammatory breast cancer
    Overmoyer, Beth
    Regan, Meredith
    Hu, Jiani
    Nakhlis, Faina
    Dominici, Laura
    Lin, Nancy U.
    Freedman, Rachel
    Morganstern, Daniel E.
    Partridge, Ann H.
    Schlosnagle, Emily J.
    Hirshfield-Bartek, Judi
    Bellon, Jennifer
    Morikawa, Aki
    Harrison, Beth T.
    Winer, Eric
    CANCER RESEARCH, 2018, 78 (04)
  • [9] Frequent pathologic complete responses seen with neoadjuvant q4week carboplatin and weekly paclitaxel ± weekly trastuzumab in resectable and locally advanced breast cancer: a Brown University Oncology Group (BrUOG) Study.
    Fenton, MA
    Ries, LM
    Strenger, R
    Dizon, DS
    Legare, RD
    Joseph, PJ
    Theall, KP
    Graves, TA
    Gass, JS
    Sikov, WM
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S224 - S225
  • [10] Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer
    Yu, Anthony F.
    Manrique, Carlos
    Pun, Shawn
    Liu, Jennifer E.
    Mara, Elton
    Fleisher, Amartin
    Patil, Sujata
    Jones, Lee W.
    Steingart, Richard M.
    Hudis, Clifford A.
    Dang, Chau T.
    ONCOLOGIST, 2016, 21 (04): : 418 - 424
12345